S100A11

Across TCGA pan-cancer cohorts, S100A11 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated S100A11 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher S100A11 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated S100A11 expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

GBM, CCRCC, and PDAC are the cancer types where S100A11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Tertile	All	0.389	0.762	<.001	23	view →
CCRCC	DFS	Tertile	III,IV	0.355	0.767	.001	20	view →
PDAC	OS	Median	All	0.714	0.927	.015	10	view →
UCEC	DFS	Tertile	All	0.986	0.854	.024	6	view →
HNSC	OS	Median	II,III,IV	1.000	0.956	.031	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

S100A11–GBM (OS)

Open the GBM breakdown →